Tapentadol extended release in the management of peripheral diabetic neuropathic pain

被引:30
|
作者
Vadivelu, Nalini [1 ]
Kai, Alice [2 ]
Maslin, Benjamin [1 ]
Kodumudi, Gopal [3 ]
Legler, Aron [1 ]
Berger, Jack M. [4 ]
机构
[1] Yale Univ, Sch Med, Dept Anesthesiol, New Haven, CT 06520 USA
[2] SUNY Stony Brook, Sch Med, Stony Brook, NY 11794 USA
[3] Tulane Univ, Dept Struct & Cellular Biol, New Orleans, LA 70118 USA
[4] Univ So Calif, Keck Sch Med, Dept Anesthesiol, Los Angeles, CA 90033 USA
关键词
chronic pain; neuropathic pain; pharmacology; analgesia; pain management; OPIOID RECEPTOR AGONIST; LOW-BACK-PAIN; OXYCODONE CONTROLLED-RELEASE; RANDOMIZED CONTROLLED-TRIAL; INDUCED BOWEL DYSFUNCTION; DOUBLE-BLIND; PROLONGED-RELEASE; CHRONIC OSTEOARTHRITIS; PHARMACOLOGICAL MANAGEMENT; MORPHINE ANALGESIA;
D O I
10.2147/TCRM.S32193
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Tapentadol, a mu-opioid agonist and norepinephrine reuptake inhibitor, has been found to be an effective medication for a wide variety of chronic pain conditions, including back pain, cancer-related pain, and arthritic pain. It has also been found to have fewer gastrointestinal side effects than more traditional opioid-based therapies. More recently, tapentadol extended release has been demonstrated to be effective in the management of painful diabetic neuropathy, an often debilitating condition affecting approximately one-third of all patients with diabetes. This review highlights the most up-to-date basic and clinical studies by focusing on the mechanisms of action of tapentadol and its clinical efficacy, especially with regard to painful diabetic neuropathy.
引用
收藏
页码:95 / 105
页数:11
相关论文
共 50 条
  • [21] Management of peripheral neuropathic pain
    Stacey, BR
    AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION, 2005, 84 (03) : S4 - S16
  • [22] A Pooled Analysis Evaluating the Efficacy and Tolerability of Tapentadol Extended Release for Chronic, Painful Diabetic Peripheral Neuropathy
    Schwartz, Sherwyn
    Etropolski, Mila S.
    Shapiro, Douglas Y.
    Rauschkolb, Christine
    Vinik, Aaron I.
    Lange, Bernd
    Cooper, Kimberly
    Van Hove, Ilse
    Haeussler, Juergen
    CLINICAL DRUG INVESTIGATION, 2015, 35 (02) : 95 - 108
  • [23] Duloxetine for the management of diabetic peripheral neuropathic pain: Evaluation of functional outcomes
    Armstrong, David G.
    Chappell, Amy S.
    Le, Trong K.
    Kajdasz, Daniel K.
    Backonja, Miroslav
    D'Souza, Deborah N.
    Russell, James M.
    PAIN MEDICINE, 2007, 8 (05) : 410 - 418
  • [24] Pharmacology Update: Tapentadol for Neuropathic Pain
    Pierce, Deidre M.
    Shipstone, Emmanuel
    AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE, 2012, 29 (08): : 663 - 666
  • [25] Correction to: Tapentadol Prolonged Release: A Review in Pain Management
    Emma D. Deeks
    Drugs, 2019, 79 : 589 - 589
  • [26] Fulranumab for treatment of diabetic peripheral neuropathic pain
    Wang, Hao
    Romano, Gary
    Frustaci, Mary Ellen
    Bohidar, Norm
    Ma, Huizhong
    Sanga, Panna
    Ness, Seth
    Russell, Lucille J.
    Fedgchin, Margaret
    Kelly, Kathleen M.
    Thipphawong, John
    NEUROLOGY, 2014, 83 (07) : 628 - 637
  • [27] Diabetic peripheral neuropathic pain: Case studies
    Belgrade, MJ
    Cole, BE
    McCarberg, BH
    McLean, MJ
    MAYO CLINIC PROCEEDINGS, 2006, 81 (04) : S26 - S32
  • [28] Diabetic Peripheral Neuropathic Pain: Is Gabapentin Effective?
    Hyatt, Joel D.
    Daniel, Dale
    Tran, Quynhlam V.
    Millares, Mirta
    Kubota, Debbie R.
    AMERICAN FAMILY PHYSICIAN, 2011, 84 (05) : 480 - 482
  • [29] Cymbalta approved for diabetic peripheral neuropathic pain
    不详
    DRUG NEWS & PERSPECTIVES, 2004, 17 (07) : 487 - 487
  • [30] Duloxetine in the treatment of diabetic peripheral neuropathic pain
    Goldstein, David J.
    FUTURE NEUROLOGY, 2006, 1 (06) : 700 - 711